Figure 6
In vivo validation of sulfasalazine, fluoxetine, clozapine and betulinic acid in acute myeloid leukemia (AML) mouse models. (a) 250 mg kg−1 Sulfasalazine decreased the rate of tumor growth compared with vehicle-treated control over a course of 21 days. (b) Image of tumor from mouse treated with 250 mg kg−1 sulfasalazine compared with control. (c) 30 mg kg−1 Fluoxetine decreased the rate of tumor growth compared with vehicle-treated control over a course of 21 days. (d) Image of tumor from mouse treated with 250 mg kg−1 fluoxetine compared with control. (e) 20 mg kg−1 Betulinic acid decreased the rate of tumor growth compared with vehicle-treated control over a course of 21 days. (f) 1 mg kg−1 Clozapine decreases the rate of tumor growth compared with vehicle-treated control over a course of 21 days.
